Scientific evidence and evidence-based practice (EBP): scope and limitations

Wednesday 30 September 2015
A2*     Session accredited under ACPE, UAN: 0579-0000-15-002-L04-P (3.0 contact hours)

Organised by the FIP Academic Pharmacy Section 

If the practice is to be science-based and evidence-driven, it is necessary to first fully understand what scientific evidence is and be able to differentiate it from what may be sold as scientific evidence (e.g. pseudoscience). While the science is driven by the desire to seek answers to a particular question, whatever the answers may be, pseudoscience is driven by the desire to convince of a particular answer, usually influenced by vested interests such as economic interests. Having an understanding of scientific evidence is however not sufficient in itself for successful translation into evidence-based-practice (EBP). The pharmacist must be aware of various models of EBP and be able to customise it to their local environment. In this session, participants will learn about these concepts in order to educate students and practitioners to use scientific evidence and EBP.

Learning objectives

Knowledge-based session

At the conclusion of this session, participants will be able to:

  1. Define scientific evidence and list its essential characteristics.
  2. Distinguish between scientific and non-scientific study methods and evidence.
  3. Demonstrate how pseudoscience can be sold as science to influence both practitioners and patients.
  4. Challenge various models for EBP and determine which may be best for their local environment.
  5. Identify the value and limitations of cutting edge science and its applicability, or the lack thereof, to current practice.

Chair: Stephen Chapman (Keele University, UK)


14:30 1) Scientific and non-scientific study methods and evidence
Vimal Kishore (Xavier University of Louisiana, USA)

15:15 2) Models for EBP-based therapeutic decision making
Toyin Tofade (University of Maryland, USA)

16:00 Break

16:15 3) Value and limitations of cutting-edge science (e.g. gene therapy and pharmacogenomics) to patient care here and now
Ichiro Ieiri (Kyushu University, Japan)

17:00 4) Panel discussion
Moderator: Stephen Chapman (Keele University, UK)

17:20 5) Real-time summarisation
Stephen Chapman (Keele University, UK)